ORIGINAL ARTICLE
Year : 2017  |  Volume : 19  |  Issue : 6  |  Page : 666-671

Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review


1 Department of Urology, West China Hospital, Sichuan University, Chengdu, China
2 Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
3 Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
4 Department of Cardiovascular and Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China

Correspondence Address:
Dr. Lu Yang
Department of Urology, West China Hospital, Sichuan University, Chengdu, China; Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

Dr. Qiang Wei
Department of Urology, West China Hospital, Sichuan University, Chengdu, China; Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.190327

Rights and Permissions

The aim of this study is to investigate the effect of statins type or even when grouping statins by hydrophilic or hydrophobic nature on prostate cancer risk. A literature search was performed without language restrictions using the databases of PubMed (1984.1-2015.3), MEDLINE (1984.1-2015.3), and EMBASE (1990.1-2015.3). Two independent reviewers appraised eligible studies and extracted data. Weighted averages were reported as relative risk (RR) with 95% confidence intervals (CI). Statistic heterogeneity scores were assessed with the standard Cochran's Q-test and I2 statistic. Publication bias was detected using the Begg's and Egger's tests. All statistical analyses were conducted by STATA version 10. Finally, fourteen studies were included in the meta-analysis. Both hydrophilic and hydrophobic statins showed no association with incidence of prostate cancer (RR = 1.00, 95% CI: 0.82-1.17; RR = 0.90, 95% CI: 0.73-1.08, respectively). Meanwhile, the risk of prostate cancer was not reduced in simvastatin (RR = 0.89, 95% CI: 0.72-1.05), pravastatin (RR = 1.02, 95% CI: 0.94-1.11), atorvastatin (RR = 0.89, 95% CI: 0.76-1.02), fluvastatin (RR = 0.99, 95% CI: 0.97-1.01), or lovastatin users (RR = 0.94, 95% CI: 0.79-1.08). The funnel plot showed that there was no publication bias. The results showed that statins had a neutral effect on prostate cancer risk; hydrophilic and hydrophobic statins as well as any subtype of statins did not affect the risk of prostate cancer.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3856    
    Printed240    
    Emailed0    
    PDF Downloaded559    
    Comments [Add]    
    Cited by others 18    

Recommend this journal